Part I. Conceptual Framework 1. The definition of precision medicine in neurodegenerative disorders and the one disease-many-diseases tension 2. Models of precision medicine for neurodegeneration 3. Pathology versus pathogenesis: rationale and pitfalls in the clinicopathology model of neurodegeneration 4. The rule of mixed pathology: "Co-pathology" or reconsideration of disease nosology? 5. Neurodegenerative Disorders: From clinicopathology convergence to systems biology divergence 6. The emergence of genotypic divergence and future precision medicine applications 7.

Lessons from other fields of medicine, Part 1: Breast cancer 8. Lessons from other fields of medicine, Part 2: Cystic fibrosis 9. Lessons learned from evolving frameworks in adult glioblastoma Part II. Pitfalls in Definitions, Cohorts, and Measures of Progression 10. Finding the falsification threshold of the toxic proteinopathy hypothesis in neurodegeneration 11. The theoretical problems of "Prodrome" and "Phenoconversion" in neurodegeneration 12. The dilemma between milestones of progression vs. clinical scales in Parkinson's disease 13.

Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: convergence or divergence? Lessons from Alzheimer's Disease and synucleinopathies 14. Challenges in the study of individuals at risk for Parkinson disease 15. The challenging quest of neuroimaging: From clinical to molecular-based subtyping of Parkinson disease and atypical parkinsonisms.